Published in Nanomedicine (Lond) on July 01, 2010
Near infrared fluorescence-guided real-time endoscopic detection of peritoneal ovarian cancer nodules using intravenously injected indocyanine green. Int J Cancer (2011) 1.12
Advances in the field of nanooncology. BMC Med (2010) 1.11
Chemical nature and structure of organic coating of quantum dots is crucial for their application in imaging diagnostics. Int J Nanomedicine (2011) 0.85
Molecular Imaging of Pancreatic Cancer with Antibodies. Mol Pharm (2015) 0.80
Potential applications of quantum dots in mapping sentinel lymph node and detection of micrometastases in breast carcinoma. J Breast Cancer (2013) 0.76
Current Status and Future Direction of Nanomedicine: Focus on Advanced Biological and Medical Applications. Nucl Med Mol Imaging (2016) 0.75
Quantum dots for live cells, in vivo imaging, and diagnostics. Science (2005) 21.62
In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol (2004) 17.47
Renal clearance of quantum dots. Nat Biotechnol (2007) 12.54
Imaging in the era of molecular oncology. Nature (2008) 11.10
Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol (2003) 11.09
Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg (1992) 9.97
Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol (2002) 7.92
Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking. Science (2003) 7.33
Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat Biotechnol (2002) 7.19
The FLARE intraoperative near-infrared fluorescence imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol (2009) 6.15
The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer (2005) 5.83
Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett (2006) 5.63
Imaging of angiogenesis: from microscope to clinic. Nat Med (2003) 5.51
Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A (2002) 5.35
Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat Biotechnol (2004) 4.85
Self-illuminating quantum dot conjugates for in vivo imaging. Nat Biotechnol (2006) 4.60
Noninvasive imaging of quantum dots in mice. Bioconjug Chem (2004) 4.59
Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci U S A (2000) 4.25
Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: feasibility study. Radiology (2008) 4.15
Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol (2009) 4.06
Image-guided oncologic surgery using invisible light: completed pre-clinical development for sentinel lymph node mapping. Ann Surg Oncol (2006) 3.98
Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology (2003) 3.71
Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer (2005) 3.62
New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35
Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med (2008) 3.15
Sentinel lymph node imaging using quantum dots in mouse tumor models. Bioconjug Chem (2007) 2.98
Targeted bulk-loading of fluorescent indicators for two-photon brain imaging in vivo. Nat Protoc (2006) 2.95
Upconversion fluorescence imaging of cells and small animals using lanthanide doped nanocrystals. Biomaterials (2007) 2.80
Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J Am Chem Soc (2008) 2.79
Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat Med (2004) 2.78
One at a time, live tracking of NGF axonal transport using quantum dots. Proc Natl Acad Sci U S A (2007) 2.74
Intraoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots. Ann Thorac Surg (2005) 2.52
Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett (2007) 2.46
Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett (2009) 2.37
Upconversion multicolor fine-tuning: visible to near-infrared emission from lanthanide-doped NaYF4 nanoparticles. J Am Chem Soc (2008) 2.26
Tracking individual kinesin motors in living cells using single quantum-dot imaging. Nano Lett (2006) 2.20
In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res (2007) 2.19
High contrast in vitro and in vivo photoluminescence bioimaging using near infrared to near infrared up-conversion in Tm3+ and Yb3+ doped fluoride nanophosphors. Nano Lett (2008) 2.13
Multispectral imaging in biology and medicine: slices of life. Cytometry A (2006) 2.00
Sentinel lymph node mapping of the gastrointestinal tract by using invisible light. Ann Surg Oncol (2006) 1.99
Intraoperative identification of esophageal sentinel lymph nodes with near-infrared fluorescence imaging. J Thorac Cardiovasc Surg (2005) 1.98
Cell-penetrating quantum dots based on multivalent and endosome-disrupting surface coatings. J Am Chem Soc (2007) 1.95
New opportunities: the use of nanotechnologies to manipulate and track stem cells. Cell Stem Cell (2008) 1.82
Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging. ACS Nano (2007) 1.70
Core/Shell semiconductor nanocrystals. Small (2009) 1.68
Real-time intraoperative assessment of the extrahepatic bile ducts in rats and pigs using invisible near-infrared fluorescent light. Surgery (2008) 1.60
Real-time intraoperative ureteral guidance using invisible near-infrared fluorescence. J Urol (2007) 1.57
H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging. ACS Chem Biol (2009) 1.56
Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst (2004) 1.55
Imaging of the lymphatic system: new horizons. Contrast Media Mol Imaging (2006) 1.46
Quantum dots for in vivo small-animal imaging. J Nucl Med (2009) 1.35
Self-assembled quantum dot-peptide bioconjugates for selective intracellular delivery. Bioconjug Chem (2006) 1.34
Real-time, near-infrared, fluorescence-guided identification of the ureters using methylene blue. Surgery (2010) 1.29
In vivo real-time, multicolor, quantum dot lymphatic imaging. J Invest Dermatol (2009) 1.26
Real time in vivo non-invasive optical imaging using near-infrared fluorescent quantum dots. Acad Radiol (2005) 1.24
Delivery of gadolinium-labeled nanoparticles to the sentinel lymph node: comparison of the sentinel node visualization and estimations of intra-nodal gadolinium concentration by the magnetic resonance imaging. J Control Release (2006) 1.24
Optical imaging-guided cancer therapy with fluorescent nanoparticles. J R Soc Interface (2009) 1.22
Two-color lymphatic mapping using Ig-conjugated near infrared optical probes. J Invest Dermatol (2007) 1.22
Multicolor imaging of lymphatic function with two nanomaterials: quantum dot-labeled cancer cells and dendrimer-based optical agents. Nanomedicine (Lond) (2009) 1.15
Quantum dot bioconjugates for in vitro diagnostics & in vivo imaging. Cancer Biomark (2008) 1.15
Clinical implications of near-infrared fluorescence imaging in cancer. Future Oncol (2009) 1.07
Detection of cell and tissue surface antigens using up-converting phosphors: a new reporter technology. Anal Biochem (1999) 1.05
Fluorescent nanocrystals for use in early cervical cancer detection. Gynecol Oncol (2005) 1.05
Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives. Nanomedicine (Lond) (2008) 1.01
High sensitivity detection of cancer in vivo using a dual-controlled activation fluorescent imaging probe based on H-dimer formation and pH activation. Mol Biosyst (2010) 1.00
Fluorescence correlation spectroscopy using quantum dots: advances, challenges and opportunities. Phys Chem Chem Phys (2007) 1.00
Quantum dots for tracking dendritic cells and priming an immune response in vitro and in vivo. PLoS One (2008) 0.99
Qdot nanocrystal conjugates conjugated to bombesin or ANG II label the cognate G protein-coupled receptor in living cells. Am J Physiol Cell Physiol (2005) 0.98
Quantum dots and peptides: a bright future together. Biopolymers (2007) 0.97
Altered membrane dynamics of quantum dot-conjugated integrins during osteogenic differentiation of human bone marrow derived progenitor cells. Biophys J (2006) 0.96
Bronchoscopy for the diagnosis and staging of lung cancer. Semin Respir Crit Care Med (2008) 0.95
Noninvasive imaging of dendritic cell migration into lymph nodes using near-infrared fluorescent semiconductor nanocrystals. FASEB J (2008) 0.94
Cationic lipid-mediated gene transfer: current concepts. Curr Opin Mol Ther (1999) 0.92
Immunofluorescence detection with quantum dot bioconjugates for hepatoma in vivo. J Biomed Opt (2007) 0.91
Quantum dots bearing lectin-functionalized nanoparticles as a platform for in vivo brain imaging. Bioconjug Chem (2008) 0.90
Fluorescence cystoscopy: is it ready for use in routine clinical practice? Curr Opin Urol (2006) 0.85
Principle and clinical usefulness of the infrared fluorescence endoscopy. J Med Invest (2006) 0.84
Neurosurgery and quantum dots: part I--state of the art. Neurosurgery (2009) 0.76
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Imaging of angiogenesis: from microscope to clinic. Nat Med (2003) 5.51
Rapid cancer detection by topically spraying a γ-glutamyltranspeptidase-activated fluorescent probe. Sci Transl Med (2011) 4.72
Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol (2013) 4.64
Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) (2008) 4.08
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med (2007) 3.88
New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev (2010) 3.35
Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am J Hum Genet (2005) 3.26
Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med (2008) 3.15
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology (2010) 3.12
Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79
Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med (2011) 2.76
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71
Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol (2013) 2.62
Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol (2012) 2.59
Correlation of magnetic resonance imaging tumor volume with histopathology. J Urol (2012) 2.55
In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res (2009) 2.51
Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett (2007) 2.46
11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med (2012) 2.42
Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology (2010) 2.38
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood (2004) 2.27
Toxicity of organic fluorophores used in molecular imaging: literature review. Mol Imaging (2009) 2.21
MRI of tumor angiogenesis. J Magn Reson Imaging (2007) 2.19
D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol (2011) 2.10
In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res (2007) 2.01
Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer (2013) 1.97
Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol (2007) 1.92
Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol (2009) 1.89
Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int (2007) 1.86
Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. Nano Lett (2006) 1.80
Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res (2007) 1.76
Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol (2009) 1.76
Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. Acc Chem Res (2010) 1.74
Percutaneous radio frequency ablation of small renal tumors: initial results. J Urol (2002) 1.74
A novel magnetic crystal-lipid nanostructure for magnetically guided in vivo gene delivery. Nat Nanotechnol (2009) 1.72
Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging. ACS Nano (2007) 1.70
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery (2007) 1.67
Radiologic manifestations of Proteus syndrome. Radiographics (2004) 1.66
In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia (2007) 1.65
Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res (2002) 1.64
A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate. Cancer Res (2007) 1.64
Chondroitin-4-sulfation negatively regulates axonal guidance and growth. J Cell Sci (2008) 1.61
H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging. ACS Chem Biol (2009) 1.56
Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano (2012) 1.56
Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst (2004) 1.55
In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol Cancer Ther (2009) 1.55
Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug Chem (2012) 1.55
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol (2006) 1.46
Imaging of the lymphatic system: new horizons. Contrast Media Mol Imaging (2006) 1.46
An enzymatically activated fluorescence probe for targeted tumor imaging. J Am Chem Soc (2007) 1.46
Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. J Urol (2007) 1.43
A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J Magn Reson Imaging (2007) 1.43
Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int (2012) 1.42
Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol Pharm (2009) 1.42
Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies. Radiology (2013) 1.39
Synthesis, characterization, and biological evaluation of integrin alphavbeta3-targeted PAMAM dendrimers. Mol Pharm (2008) 1.39
A self-quenched galactosamine-serum albumin-rhodamineX conjugate: a "smart" fluorescent molecular imaging probe synthesized with clinically applicable material for detecting peritoneal ovarian cancer metastases. Clin Cancer Res (2007) 1.38
Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjug Chem (2011) 1.37
Activatable fluorescent molecular imaging of peritoneal metastases following pretargeting with a biotinylated monoclonal antibody. Cancer Res (2007) 1.37
Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. Chem Soc Rev (2011) 1.36
Intravoxel incoherent motion MR imaging for prostate cancer: an evaluation of perfusion fraction and diffusion coefficient derived from different b-value combinations. Magn Reson Med (2012) 1.34
Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia (2007) 1.33
Increased (18)F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. J Nucl Med (2002) 1.30
Multicolor in vivo targeted imaging to guide real-time surgery of HER2-positive micrometastases in a two-tumor coincident model of ovarian cancer. Cancer Sci (2009) 1.29
D-galactose receptor-targeted in vivo spectral fluorescence imaging of peritoneal metastasis using galactosamin-conjugated serum albumin-rhodamine green. J Biomed Opt (2007) 1.29
Use of patient-specific MRI-based prostate mold for validation of multiparametric MRI in localization of prostate cancer. Urology (2012) 1.28
Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology. J Magn Reson Imaging (2013) 1.27
Multiparametric MRI and prostate cancer diagnosis and risk stratification. Curr Opin Urol (2012) 1.26